Celularity (NASDAQ:CELU) Stock Price Down 8.8%

Celularity Inc. (NASDAQ:CELU)’s share price was down 8.8% during trading on Wednesday . The company traded as low as $2.65 and last traded at $2.68. Approximately 25,540 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 104,829 shares. The stock had previously closed at $2.94.

Celularity Price Performance

The business’s 50 day moving average is $2.92 and its 200 day moving average is $3.34.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Celularity stock. Keynote Financial Services LLC bought a new stake in shares of Celularity Inc. (NASDAQ:CELU) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned approximately 0.08% of Celularity at the end of the most recent reporting period. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.